OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of expertise in ...

The partnership between OGT and QIAGEN Digital Insights (QDI), expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq™ ...